Literature DB >> 17449730

Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models.

Eva García-Alegría1, Berta Ibáñez, Mónica Mínguez, Marisa Poch, Alberto Valiente, Arantza Sanz-Parra, Cristina Martinez-Bouzas, Elena Beristain, Maria-Isabel Tejada.   

Abstract

Fragile X syndrome is caused by the absence or reduction of the fragile X mental retardation protein (FMRP) because FMR1 gene expression is reduced. Alleles with repeat sizes of 55-200 are classified as premutations, and it has been demonstrated that FMR1 expression is elevated in the premutation range. However, the majority of the studies reported were performed in males. We studied FMR1 expression in 100 female fragile X family members from the northern region of Spain using quantitative (fluorescence) real-time polymerase chain reaction. Of these 100 women, 19 had normal alleles, 19 were full mutation carriers, and 62 were premutation carriers. After confirming differences between the three groups of females, and increased levels of the FMR1 transcript among premutation carriers, we found that the relationship between mRNA levels and repeat size is nonlinear. These results were obtained using a novel methodology that, based on the size of the CGG repeats, allows us to find out the most probable threshold from which the relationship between CGG repeat number and mRNA levels changes. Using this approach, a significant positive correlation between CGG repeats and total mRNA levels has been found in the premutation range <100 CGG, but this correlation diminishes from 100 onward. However, when correcting by the X inactivation ratio, mRNA levels increase as the number of CGG repeats increases, and this increase is highly significant over 100 CGG. We suggest that due to skewed X inactivation, mRNA levels tend to normalize in females when the number of CGG repeats increases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449730      PMCID: PMC1852810          DOI: 10.1261/rna.206307

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  20 in total

1.  A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA.

Authors:  F Tassone; R J Hagerman; A K Taylor; P J Hagerman
Journal:  J Med Genet       Date:  2001-07       Impact factor: 6.318

2.  Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers.

Authors:  A Kenneson; F Zhang; C H Hagedorn; S T Warren
Journal:  Hum Mol Genet       Date:  2001-07-01       Impact factor: 6.150

3.  Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.

Authors:  R J Hagerman; M Leehey; W Heinrichs; F Tassone; R Wilson; J Hills; J Grigsby; B Gage; P J Hagerman
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

4.  Transcription of the FMR1 gene in individuals with fragile X syndrome.

Authors:  F Tassone; R J Hagerman; W D Chamberlain; P J Hagerman
Journal:  Am J Med Genet       Date:  2000

5.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

6.  Estimating regression models with unknown break-points.

Authors:  Vito M R Muggeo
Journal:  Stat Med       Date:  2003-10-15       Impact factor: 2.373

7.  Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA.

Authors:  F Tassone; R J Hagerman; D Z Loesch; A Lachiewicz; A K Taylor; P J Hagerman
Journal:  Am J Med Genet       Date:  2000-09-18

Review 8.  Premature ovarian failure in the fragile X syndrome.

Authors:  S L Sherman
Journal:  Am J Med Genet       Date:  2000

9.  Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates.

Authors:  Sébastien Jacquemont; Randi J Hagerman; Maureen Leehey; Jim Grigsby; Lin Zhang; James A Brunberg; Claudia Greco; Vincent Des Portes; Tristan Jardini; Richard Levine; Elizabeth Berry-Kravis; W Ted Brown; Stephane Schaeffer; John Kissel; Flora Tassone; Paul J Hagerman
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

Review 10.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

View more
  17 in total

1.  Fibromyalgia in fragile X mental retardation 1 gene premutation carriers.

Authors:  Maureen A Leehey; Wendi Legg; Flora Tassone; Randi Hagerman
Journal:  Rheumatology (Oxford)       Date:  2011-09-16       Impact factor: 7.580

2.  Use of human-derived stem cells to create a novel, in vitro model designed to explore FMR1 CGG repeat instability amongst female premutation carriers.

Authors:  Stephanie L F Gustin; Guangwen Wang; Valerie M Baker; Gary Latham; Vittorio Sebastiano
Journal:  J Assist Reprod Genet       Date:  2018-06-20       Impact factor: 3.412

3.  Microdeletions including FMR1 in three female patients with intellectual disability - further delineation of the phenotype and expression studies.

Authors:  A M Zink; E Wohlleber; H Engels; O K Rødningen; K Ravn; S Heilmann; J Rehnitz; N Katzorke; C Kraus; S Blichfeldt; P Hoffmann; H Reutter; F F Brockschmidt; M Kreiß-Nachtsheim; P H Vogt; T E Prescott; Z Tümer; J A Lee
Journal:  Mol Syndromol       Date:  2014-01-29

4.  Examination of FMR1 transcript and protein levels among 74 premutation carriers.

Authors:  Emmanuel Peprah; Weiya He; Emily Allen; Tiffany Oliver; Alex Boyne; Stephanie L Sherman
Journal:  J Hum Genet       Date:  2009-11-20       Impact factor: 3.172

5.  Investigation of phenotypes associated with mood and anxiety among male and female fragile X premutation carriers.

Authors:  Jessica Ezzell Hunter; Emily Graves Allen; Ann Abramowitz; Michele Rusin; Mary Leslie; Gloria Novak; Debra Hamilton; Lisa Shubeck; Krista Charen; Stephanie L Sherman
Journal:  Behav Genet       Date:  2008-06-06       Impact factor: 2.805

Review 6.  Unstable mutations in the FMR1 gene and the phenotypes.

Authors:  Danuta Loesch; Randi Hagerman
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Relationships between age and epi-genotype of the FMR1 exon 1/intron 1 boundary are consistent with non-random X-chromosome inactivation in FM individuals, with the selection for the unmethylated state being most significant between birth and puberty.

Authors:  David E Godler; Yoshimi Inaba; Elva Z Shi; Cindy Skinner; Quang M Bui; David Francis; David J Amor; John L Hopper; Danuta Z Loesch; Randi J Hagerman; Charles E Schwartz; Howard R Slater
Journal:  Hum Mol Genet       Date:  2013-01-10       Impact factor: 6.150

8.  No evidence for a difference in neuropsychological profile among carriers and noncarriers of the FMR1 premutation in adults under the age of 50.

Authors:  Jessica Ezzell Hunter; Emily Graves Allen; Ann Abramowitz; Michele Rusin; Mary Leslie; Gloria Novak; Debra Hamilton; Lisa Shubeck; Krista Charen; Stephanie L Sherman
Journal:  Am J Hum Genet       Date:  2008-11-20       Impact factor: 11.025

9.  Molecular testing for fragile X: analysis of 5062 tests from 1105 fragile X families--performed in 12 clinical laboratories in Spain.

Authors:  María-Isabel Tejada; Guillermo Glover; Francisco Martínez; Miriam Guitart; Yolanda de Diego-Otero; Isabel Fernández-Carvajal; Feliciano J Ramos; Concepción Hernández-Chico; Elizabet Pintado; Jordi Rosell; María-Teresa Calvo; Carmen Ayuso; María-Antonia Ramos-Arroyo; Hiart Maortua; Montserrat Milà
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

10.  Sulforaphane improves mitochondrial metabolism in fibroblasts from patients with fragile X-associated tremor and ataxia syndrome.

Authors:  Eleonora Napoli; Amanda Flores; Yasmeen Mansuri; Randi J Hagerman; Cecilia Giulivi
Journal:  Neurobiol Dis       Date:  2021-06-19       Impact factor: 7.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.